CY1106064T1 - Τυποποιηση ενος εστερα τεστοστepονης για ανθρωπινη χρηση - Google Patents

Τυποποιηση ενος εστερα τεστοστepονης για ανθρωπινη χρηση

Info

Publication number
CY1106064T1
CY1106064T1 CY20061100113T CY061100113T CY1106064T1 CY 1106064 T1 CY1106064 T1 CY 1106064T1 CY 20061100113 T CY20061100113 T CY 20061100113T CY 061100113 T CY061100113 T CY 061100113T CY 1106064 T1 CY1106064 T1 CY 1106064T1
Authority
CY
Cyprus
Prior art keywords
testosterone
standardization
decanate
human use
testosterone ester
Prior art date
Application number
CY20061100113T
Other languages
English (en)
Inventor
Henrik De Nijs
Wendy Margaretha Kersemaekers
Sephanus Cornelis Schutte
Johann Gerhard Cornelis Van Bruggen
Original Assignee
N.V. Organon
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by N.V. Organon filed Critical N.V. Organon
Publication of CY1106064T1 publication Critical patent/CY1106064T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Αποκαλύπτεται μια τυποποίηση δεκανικής τεστοστερόνης για χρήση στη θεραπεία ανθρώπων. Σε αντίθεση με γνωστές τυποποιήσεις που περιλαμβάνουν δεκανική τεστοστερόνη, βρέθηκε ότι μπορούν να παραβλεφθούν οποιοιδήποτε άλλοι εστέρες τεστοστερόνης που βρίσκονται κανονικά παρόν μαζί με δεκανική τεστοστερόνη, και η τυποποίηση κατά συνέπεια περιλαμβάνει δεκανική τεστοστερόνη ως το μόνο εστέρα τεστοστερόνης.
CY20061100113T 2000-08-23 2006-01-27 Τυποποιηση ενος εστερα τεστοστepονης για ανθρωπινη χρηση CY1106064T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP00202939 2000-08-23
PCT/EP2001/009569 WO2002015938A2 (en) 2000-08-23 2001-08-17 Testosterone ester formulation for human use
EP01971928A EP1313511B1 (en) 2000-08-23 2001-08-17 Testosterone ester formulation for human use

Publications (1)

Publication Number Publication Date
CY1106064T1 true CY1106064T1 (el) 2011-06-08

Family

ID=8171940

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20061100113T CY1106064T1 (el) 2000-08-23 2006-01-27 Τυποποιηση ενος εστερα τεστοστepονης για ανθρωπινη χρηση

Country Status (15)

Country Link
US (1) US20050101517A1 (el)
EP (1) EP1313511B1 (el)
JP (1) JP2004506698A (el)
CN (1) CN1248738C (el)
AT (1) ATE311201T1 (el)
AU (2) AU2001291775B2 (el)
BR (1) BR0113376A (el)
CA (1) CA2415349A1 (el)
CY (1) CY1106064T1 (el)
DE (1) DE60115464T2 (el)
DK (1) DK1313511T3 (el)
ES (1) ES2253423T3 (el)
IL (2) IL153648A0 (el)
MX (1) MXPA03001147A (el)
WO (1) WO2002015938A2 (el)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200404552A (en) * 2002-05-30 2004-04-01 Akzo Nobel Nv Self administered contraception
JO2505B1 (en) 2003-03-14 2009-10-05 باير شيرنغ فارما اكتنجيسيلشافت Pharmacy methods and formulations for obtaining acceptable serum testosterone levels
IL157535A0 (en) * 2003-08-21 2004-03-28 Topimed Ltd Preparations for the prevention of skin atrophy
US9993558B2 (en) 2004-10-01 2018-06-12 Ramscor, Inc. Sustained release eye drop formulations
US8541413B2 (en) * 2004-10-01 2013-09-24 Ramscor, Inc. Sustained release eye drop formulations
US20080038316A1 (en) * 2004-10-01 2008-02-14 Wong Vernon G Conveniently implantable sustained release drug compositions
EP2452670A1 (en) * 2004-10-01 2012-05-16 Ramscor, Inc. Conveniently implantable sustained release drug compositions
DK2985026T3 (da) 2005-04-15 2022-10-31 Clarus Therapeutics Inc Farmaceutiske leveringssystemer til hydrofobe lægemidler og sammensætninger dermed
US8492369B2 (en) 2010-04-12 2013-07-23 Clarus Therapeutics Inc Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same
CA2822435C (en) * 2009-12-31 2018-09-11 Differential Drug Development Associates, Llc Modulation of solubility, stability, absorption, metabolism, and pharmacokinetic profile of lipophilic drugs by sterols
US20180153904A1 (en) 2010-11-30 2018-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US9034858B2 (en) 2010-11-30 2015-05-19 Lipocine Inc. High-strength testosterone undecanoate compositions
US9358241B2 (en) 2010-11-30 2016-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US20120148675A1 (en) 2010-12-10 2012-06-14 Basawaraj Chickmath Testosterone undecanoate compositions
CN105188670B (zh) 2013-03-15 2018-11-02 马留斯医药有限责任公司 乳液制剂
TW201521731A (zh) * 2013-03-15 2015-06-16 利波辛股份有限公司 用於口服之脂平衡的長鏈睪固酮酯
WO2015100406A1 (en) 2013-12-26 2015-07-02 Clarus Therapeutics, Inc. Use of oral pharmaceutical products combining testosterone esters with hypolipidemic agents
WO2016033549A2 (en) 2014-08-28 2016-03-03 Lipocine Inc. (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
WO2016033556A1 (en) 2014-08-28 2016-03-03 Lipocine Inc. BIOAVAILABLE SOLID STATE (17-β)-HYDROXY-4-ANDROSTEN-3-ONE ESTERS
US10188602B2 (en) 2016-09-29 2019-01-29 Gesea Biosciences Inc. Bioerodible implant for long-term drug delivery and associated methods of manufacture and use
US20180147215A1 (en) 2016-11-28 2018-05-31 Lipocine Inc. Oral testosterone undecanoate therapy

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB465331A (en) * 1935-10-05 1937-05-05 Chem Ind Basel Manufacture of new esters of polynuclear cyclic oxyketones
NL189235C (nl) * 1974-02-28 1993-02-16 Akzo Nv Werkwijze voor de bereiding van een oraal toe te dienen farmaceutisch preparaat met androgene werking.
US4098802A (en) * 1975-02-18 1978-07-04 Akzona Incorporated Oral pharmaceutical preparation having androgenic activity
US4147783A (en) * 1974-02-28 1979-04-03 Akzona Incorporated Oral pharmaceutical preparation
NL7506407A (nl) * 1975-05-30 1976-12-02 Akzo Nv Werkwijze ter bereiding van een oraal werkzaam far- maceutisch preparaat.
GB1567515A (en) * 1976-05-28 1980-05-14 Akzo Nv Esters of testo-sterone and 5 -dihydro-testosterone
ES2054784T3 (es) * 1987-08-08 1994-08-16 Akzo Nv Un metodo para la fabricacion de un implante.
US6063395A (en) * 1998-11-12 2000-05-16 Leiras Oy Drug delivery device especially for the delivery of progestins and estrogens
US7025979B2 (en) * 2000-02-15 2006-04-11 Schering Ag Male contraceptive formulation comprising norethisterone

Also Published As

Publication number Publication date
US20050101517A1 (en) 2005-05-12
MXPA03001147A (es) 2003-10-06
AU9177501A (en) 2002-03-04
EP1313511B1 (en) 2005-11-30
ES2253423T3 (es) 2006-06-01
ATE311201T1 (de) 2005-12-15
BR0113376A (pt) 2003-07-15
AU2001291775B2 (en) 2005-09-08
WO2002015938A3 (en) 2002-08-15
DE60115464D1 (de) 2006-01-05
IL153648A0 (en) 2003-07-06
DK1313511T3 (da) 2006-03-20
DE60115464T2 (de) 2006-06-14
IL153648A (en) 2009-02-11
WO2002015938A2 (en) 2002-02-28
WO2002015938A8 (en) 2004-03-04
EP1313511A2 (en) 2003-05-28
CN1443078A (zh) 2003-09-17
JP2004506698A (ja) 2004-03-04
CN1248738C (zh) 2006-04-05
CA2415349A1 (en) 2002-02-28

Similar Documents

Publication Publication Date Title
CY1106064T1 (el) Τυποποιηση ενος εστερα τεστοστepονης για ανθρωπινη χρηση
MX2008001503A (es) Composicion cosmetica o dermatologica para la prevencion o el tratamiento de piel sensible o seca.
ECSP034430A (es) Esteres oxigenados de acidos 4-yodo fenilamino benzhidroxamcios
BRPI0519242A2 (pt) uso derivados de 1-aminociclohexano para o tratamento de esclerose méltipla, instabilidade emocional e paralisia pseudobulbar
CR7786A (es) Anticuerpos neutralizantes contra gdf-8 y el uso de los mismos
CY1106628T1 (el) Τοπικες φαρμακευτικες συνθεσεις περιλαμβανουσες προανθοκυανιδινες, γλυκυρροχητινικο οξυ και τελμεστεϊνη για τη θεραπεια των δερματιτιδων
PA8481501A1 (es) 4-carboxiamino-2-metil-1,2,3,4-tetrahidroquinolinas
UY27639A1 (es) Composiciones farmacéuticas de inhibidores de la proteína de transferencia de ésteres de colesterilo
ES2124793T3 (es) Derivados de rapamicina alquilados en o y su uso, particularmente como inmunosupresores.
ATE462428T1 (de) Behandlung von entzündlichen erkrankungen
CY1108211T1 (el) Προφυλακτικη και θεραπευτικη αγωγη των μολυσματικων, αυτοανοσων και αλλεργικων νοσων με ενωσεις βασης μονοσακχαριτη
UY26864A1 (es) Composiciones farmaceúticas de inhibidores de la proteína de transferencia de colesteril éster
ES2117052T3 (es) Induccion de respuestas de linfocitos t citotoxicos.
BRPI0511707A (pt) peroxifosfatos de cálcio e sua utilização em composições dentais
DE60035574D1 (de) Formulierungen zur behandlung von krankheiten und verfahren unter deren verwendung
CY1106595T1 (el) Συνθεση πηγματος και εφαρμογη μεσω του οσχεου μιας συνθεσεως δια την θεραπευτικη αγωγη του υπογοναδισμου
CY1104971T1 (el) Παρασκευασμα αποϊνιδοτιδιου και g-csf και η χρηση του για να κινητοποιει αιμοποιητικους προγονους
ATE345769T1 (de) Selbstbräunende zusammensetzungen , die dha und propolis-extrakt enthalten
DE60116359D1 (de) Kahalalid f formulierung
BR0210101A (pt) Combinações antineoplásticas
ES2170143T3 (es) Composiciones que comprenden halofantrina en una forma especial.
NO20023102D0 (no) Metode og formulering for å behandle motstand mot antihypertensiver og lignende tilstander
ES2155517T3 (es) Derivados del acido n-acetil-neuraminico y procedimientos para su preparacion.
BR0007666A (pt) Composição cosmética com base em mentol e mentil lactato, tendo pouco odor e sendo não irritante
TR199900505T2 (el)